Business
RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older
TOKYO, October 07, 2025--RIBOMIC, Inc. (TOKYO:4591), a clinical-stage pharmaceutical company specializing in aptamer therapeutics, has conducted a Phase 2 clinical trial of umedaptanib pegol (anti-FGF2 aptamer) in pediatric patients (ages 5-14) with achondroplasia (ACH). The company announced today that the administration of the high-dose (0.6 mg/kg) subcutaneous injection (once biweekly) group (Cohort 2 Note 1) has completed the trial and demonstrated a positive impact of the test drug on the p
About this update from Ribomic, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/bb5d2124d34ba378bbcdab6b2fc643bb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/72HQG5mONzxS.EHCbqD5tA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/bb5d2124d34ba378bbcdab6b2fc643bb","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/iITMpKWLpaL8tAlMD8T90A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/bb5d2124d34ba378bbcdab6b2fc643bb","width":1024,"height":512}},"lazy":false},{"type":"text","content":"TOKYO, October 07, 2025--(BUSINESS WIRE)--RIBOMIC, Inc. (TOKYO:4591), a clinical-stage pharmaceutical company specializing in aptamer therapeutics, has conducted a Phase 2 clinical trial of umedaptanib pegol (anti-FGF2 aptamer) in pediatric patients (ages 5-14) with achondroplasia (ACH). The company announced today that the administration of the high-dose (0.6 mg/kg) subcutaneous injection (once biweekly) group (Cohort 2 Note 1) has completed the trial and demonstrated a positive impact of the test drug on the patient growth rate.","length":536,"tagName":"p"},{"type":"text","content":"In this Phase 2 clinical trial, both Cohort 1 and Cohort 2 received the same total dose of the investigational drug. Cohort 1 Note 2, which was completed earlier, consisted of a group receiving weekly subcutaneous injections of a low dose (0.3 mg/kg). In contrast, Cohort 2 consists of a high dose (0.6 mg/kg), administered every other week. The trial's objective is to confirm the efficacy, safety and durability of umedaptanib pegol.","length":439,"tagName":"p"},{"type":"text","content":"In Cohort 1, three of the five subjects who completed the dosing period showed an increased height growth rate compared to pre-treatment levels (see Observation Study Note 3), with two showing growth rates of +4.6 cm/year and +3.3 cm/year (Disclosure dated November 5, 2024). In Cohort 2, all 6 subjects completed the trial, and 5 subjects showed increased height growth rate, with 2 showing significant increases of +5.0 cm/year and +2.0 cm/year. The results for these 4 subjects with markedly increased height growth exceeded the average...